Related Experiment Video
Updated: Aug 6, 2026

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System
Published on: October 29, 2019
Therapeutic potential of antisense oligonucleotides in hematological malignancies
Elie Cousin1, Agathe Picard2, Elfie Perrudin1
1Univ Rennes, CNRS, INSERM, IGDR (Institute Genetics and Development of Rennes) - UMR 6290, ERL U1305, France.
Abstract:
Antisense oligonucleotides (ASOs) are short synthetic oligonucleotides composed of DNA, RNA, or chemically modified nucleotides, that represent a promising class of therapeutics for personalized medicine. This review synthesizes the clinical evidence from published studies evaluating ASOs in myelodysplastic syndromes, acute myeloid leukemia, acute lymphoblastic leukemia and chronic lymphocytic leukemia. Preclinical investigations and early-phase clinical trials have yielded encouraging results, demonstrating manageable toxicity profiles and supporting ongoing phase II and III evaluations. Although definitive clinical efficacy in leukemia has yet to be established, advances in target identification and continuous technological innovations, highlighted in this review, are progressively overcoming pharmacological, toxicological, and formulation challenges. ASO-based therapies may thus offer a highly versatile and rapidly adaptable platform for precision medicine in leukemia. Future progress will depend on rigorous translational studies addressing delivery efficiency and off-target effects, as well as on clinical trials designed to identify optimal combination strategies. With these developments, ASOs hold the potential to become a cornerstone of next-generation, highly personalized therapies, offering renewed hope to patients with limited treatment options and establishing a paradigm for precision-targeted interventions in leukemias.
Related Concept Videos
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Inhibitors of Viral Protein Synthesis
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Experimental RNAi
Regulation of Hematopoietic Stem Cells
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
